Streetbeat News

BCDA

BioCardia, Inc.

https://www.biocardia.com

Industry

Biotechnology

BioCardia, Inc., a clinical-stage regenerative medicine company, develops cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases. Its lead therapeutic candidate is the CardiAMP Cell Therapy System for the treatment of heart failure and chronic myocardial ischemia; and allogeneic cell therapy for cardiac and pulmonary disease. The company is also developing allogeneic cells therapeutic platform, an investigational culture expanded bone marrow derived mesenchymal cell therapy, which is in Phase I/II trial for the treatment of ischemic systolic heart failure. In addition, it offers the Helix biotherapeutic delivery system that delivers therapeutics into the heart muscle with a penetrating helical needle from within the heart; and Morph deflectable guides and sheaths. The company is based in Sunnyvale, California.

Open

2.35

Mkt cap

7.9M

Volume

83K

High

2.38

P/E Ratio

-0.43

52-wk high

23.25

Low

2.25

Div yield

N/A

52-wk low

1.96

U.S. stocks saw significant gains with the Dow Jones rising over 500 points. Home Depot (HD) reported third-quarter results that exceeded expectations, with a 3% year-on-year sales decline to $37.71 billion, surpassing analyst estimates of $35.66 billion, and an EPS of $3.81 beating the consensus of $3.58. Real estate shares led the market with a 5% surge, while energy shares had a modest increase of 0.5%. BioCardia (BCDA), INVO Bioscience (INVO), and Theseus Pharmaceuticals (THRX) experienced substantial stock price increases due to positive company developments. Conversely, The Beauty Health Company (SKIN), Kubient (KBNT), and Applied UV (AUVI) saw their shares plummet following negative financial results and company announcements.

Portfolio Pulse from Lisa Levin

November 14, 2023 | 8:10 pm

Beyond Air, Inc. (XAIR) shares dropped by 37.3% to $1.2701 due to weaker than expected quarterly results, with a loss of 51 cents per share and sales of $239,000 against expectations of $480,000. Other stocks experienced significant movements in Tuesday's mid-day session, with notable gainers including BioCardia, Inc. (BCDA), reAlpha Tech Corp. (AIRE), and Theseus Pharmaceuticals, Inc. (THRX), among others. Losers included Li-Cycle Holdings Corp. (LICY) and The Beauty Health Company (SKIN), which both saw sharp declines after reporting disappointing financial results.

Portfolio Pulse from Lisa Levin

November 14, 2023 | 7:05 pm

BioCardia's stock is up following FDA approval for Phase 3 clinical trials of CardiAMP, a cell therapy for ischemic heart failure.

Portfolio Pulse from Benzinga Newsdesk

November 14, 2023 | 6:36 pm

U.S. stocks traded higher with the Dow Jones gaining around 500 points. Real estate shares surged by 4.6%, while energy shares rose by 0.2%. The U.S. annual inflation rate decreased to 3.2% in October. BioCardia, Inc. (BCDA) soared 206% after FDA approval for a Phase 3 clinical trial. INVO Bioscience, Inc. (INVO) rose 28% after posting a narrower Q3 loss. Theseus Pharmaceuticals, Inc. (THRX) gained 50% after announcing a strategic alternatives exploration process. The Beauty Health Company (SKIN) plunged 60% due to weak Q3 results and a suspended 2025 forecast. Kubient, Inc. (KBNT) dropped 51% after announcing a voluntary delisting from Nasdaq. Applied UV, Inc. (AUVI) fell 44% after pricing a public offering. Oil and gold prices increased.

Portfolio Pulse from Lisa Levin

November 14, 2023 | 6:11 pm

HC Wainwright & Co. analyst Joseph Pantginis has reiterated a Buy rating on BioCardia (NASDAQ:BCDA) and maintained a price target of $4. This reaffirmation of the company's stock by a reputable analyst could influence investor sentiment and potentially impact the stock's short-term performance.

Portfolio Pulse from Benzinga Newsdesk

November 14, 2023 | 4:22 pm

BioCardia Inc's stock (NASDAQ:BCDA) soared by over 200% after the FDA approved its Phase 3 CardiAMP Heart Failure II study protocol. The study focuses on CardiAMP autologous cell therapy for ischemic heart failure. Interim analysis showed significant clinical improvements in patients with certain NT-proBNP levels. The final data from the ongoing trial is expected in Q4 2024. The new study will have a modified primary efficacy endpoint and eligibility requirements based on NT-proBNP levels.

Portfolio Pulse from Vandana Singh

November 14, 2023 | 4:05 pm

U.S. stocks traded higher with the Dow Jones gaining around 400 points. The NASDAQ surged 2.03% and the S&P 500 rose 1.61%. U.S. annual inflation rate slowed to 3.2% in October, below market estimates. BioCardia, Inc. soared 243% after FDA approval for a clinical trial. INVO Bioscience and Theseus Pharmaceuticals also saw significant gains. The Beauty Health Company, Kubient, Inc., and Applied UV faced sharp declines after negative reports. Oil and gold prices increased, while European and Asian markets showed mixed results.

Portfolio Pulse from Lisa Levin

November 14, 2023 | 2:50 pm

Theseus Pharmaceuticals (THRX) is exploring strategic alternatives, causing its stock to surge by 53%. BioCardia (BCDA) announced FDA approval for its Phase 3 clinical trial of CardiAMP cell therapy for ischemic heart failure, leading to a 166% stock increase. INVO BioScience (INVO) reported a smaller-than-expected GAAP EPS loss of $0.70, beating estimates by $0.17, but missed revenue targets by $0.96M, with a total revenue of $0.97M, resulting in a 51% stock jump.

Portfolio Pulse from ryanfaloona@benzinga.com

November 14, 2023 | 1:41 pm

In Tuesday's pre-market session, several healthcare stocks showed significant movement. BioCardia (BCDA) saw a substantial increase of 115.5% to $0.86, while BioXcel Therapeutics (BTAI) experienced a sharp decline of 37.9% to $3.42. Other notable gainers included Theseus Pharmaceuticals (THRX), INVO Bioscience (INVO), Genfit (GNFT), Redhill Biopharma (RDHL), and Biodexa Pharmaceuticals (BDRX). On the losing side, Harrow (HROW), Tenax Therapeutics (TENX), Akili (AKLI), Renalytix (RNLX), and TRACON Pharma (TCON) saw their stock prices fall. The movements were largely attributed to recent earnings reports.

Portfolio Pulse from Benzinga Insights

November 14, 2023 | 1:06 pm

BioCardia (NASDAQ:BCDA) reported Q3 2023 GAAP EPS of $(0.12), meeting analyst consensus. This is a 29.41% increase over losses from the same period last year. The company's quarterly sales of $357.00K beat the analyst consensus estimate of $20.00K by 1.69K percent, marking a 68.40% increase over sales from the same period last year.

Portfolio Pulse from saritha@benzinga.com

November 08, 2023 | 10:20 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.